Information Provided By:
Fly News Breaks for October 11, 2017
Oct 11, 2017 | 09:45 EDT
Mizuho analyst Difei Yang said the briefing documents for the FDA's advisory committee meeting to discuss Rhopressa make it appear that the agency's stance is favorable towards Aerie's treatment. The analyst views the FDA's modifications to Aerie's proposed language to be "very minor" and is encouraged by the language used in the indication and usage section. Yang keeps a Buy rating on Aerie Pharmaceuticals shares, which are trading higher following the posting of the meeting documents.
News For AERI From the Last 2 Days
There are no results for your query AERI
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.